Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,382
Out of 4,761 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.30 | +112.93% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $13.17 | +51.86% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $11.07 | +803.34% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $700.33 | +21.37% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $57.75 | -16.88% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $303.01 | -28.72% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $202.08 | -33.19% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $10.68 | +3.00% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $109.95 | -31.79% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $54.46 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.32 | +7.35% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.71 | +4,149.89% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $484.24 | -63.86% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $12.35 | +580.16% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $36.64 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $5.02 | +557.37% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $11.13 | +448.07% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $140.64 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.30
Upside: +112.93%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $13.17
Upside: +51.86%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $11.07
Upside: +803.34%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $700.33
Upside: +21.37%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $57.75
Upside: -16.88%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $303.01
Upside: -28.72%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $202.08
Upside: -33.19%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $10.68
Upside: +3.00%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $109.95
Upside: -31.79%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $54.46
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.32
Upside: +7.35%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.71
Upside: +4,149.89%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $484.24
Upside: -63.86%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $12.35
Upside: +580.16%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $36.64
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $5.02
Upside: +557.37%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $11.13
Upside: +448.07%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $140.64
Upside: -